Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, BioNTech SE ADR (NASDAQ: BNTX) closed at $117.53 down -2.17% from its previous closing price of $120.14. In other words, the price has decreased by -$2.17 from its previous closing price. On the day, 0.57 million shares were traded. BNTX stock price reached its highest trading level at $119.858 during the session, while it also had its lowest trading level at $116.595.
Ratios:
For a deeper understanding of BioNTech SE ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.35. For the most recent quarter (mrq), Quick Ratio is recorded 7.40 and its Current Ratio is at 7.54. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on September 24, 2024, Upgraded its rating to Overweight and sets its target price to $145 from $93 previously.
On September 17, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $96 to $150.
JP Morgan Upgraded its Underweight to Neutral on September 16, 2024, whereas the target price for the stock was revised from $91 to $125.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 14 ’24 when ATHOS KG bought 25,424 shares for $120.83 per share.
ATHOS KG bought 40,000 shares of BNTX for $4,805,228 on Oct 11 ’24. On Oct 10 ’24, another insider, ATHOS KG, who serves as the 10% Owner of the company, bought 20,000 shares for $117.47 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 27944638464 and an Enterprise Value of 10903565312. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.61 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 4.052 whereas that against EBITDA is -17.544.
Stock Price History:
Over the past 52 weeks, BNTX has reached a high of $131.49, while it has fallen to a 52-week low of $76.53. The 50-Day Moving Average of the stock is 14.86%, while the 200-Day Moving Average is calculated to be 24.28%.
Shares Statistics:
For the past three months, BNTX has traded an average of 949.67K shares per day and 654880 over the past ten days. A total of 237.73M shares are outstanding, with a floating share count of 237.11M. Insiders hold about 0.26% of the company’s shares, while institutions hold 17.88% stake in the company. Shares short for BNTX as of 1727654400 were 1859038 with a Short Ratio of 1.96, compared to 1724976000 on 2578447. Therefore, it implies a Short% of Shares Outstanding of 1859038 and a Short% of Float of 3.88.
